Johnson & Johnson (JNJ): Gary J Pruden , Exec VP, WW Chair, Med Devices of Johnson & Johnson sold 9,735 shares on Jun 7, 2016. The Insider selling transaction was reported by the company on Jun 9, 2016 to the Securities and Exchange Commission. The shares were sold at $116.03 per share for a total value of $1,129,552.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 9, 2016, Ronald A Kapusta (Controller, CAO) sold 3,000 shares at $115.79 per share price.On Feb 4, 2016, Peter Fasolo (VP, Global Human Resources) sold 151,385 shares at $104.11 per share price.Also, On Nov 24, 2015, Michael H Ullmann (VP, General Counsel) sold 17,650 shares at $102.47 per share price.On Nov 4, 2015, Dominic J Caruso (VP, Finance; CFO) sold 20,569 shares at $102.21 per share price.
Johnson & Johnson: On Thursday, Jun 9, 2016 heightened volatility was witnessed in Johnson & Johnson which led to swings in the share price. The shares opened for trading at $115.78 and hit $117.19 on the upside , eventually ending the session at $117, with a gain of 1.04% or 1.2 points. The heightened volatility saw the trading volume jump to 73,75,474 shares. The 52-week high of the share price is $117.19 and the company has a market cap of $321,825 M . The 52-week low of the share price is at $81.79.
Company has been under the radar of several Street Analysts.Johnson & Johnson is Initiated by Standpoint Research to Sell and the brokerage firm has set the Price Target at $94. The Rating was issued on May 20, 2016.Johnson & Johnson is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 125 from a previous price target of $122 .The Rating was issued on Apr 20, 2016.Johnson & Johnson is Reiterated by Piper Jaffray to Neutral and the brokerage firm has raised the Price Target to $ 106 from a previous price target of $105 .The Rating was issued on Apr 20, 2016.Johnson & Johnson is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 122 from a previous price target of $114 .The Rating was issued on Apr 15, 2016.Johnson & Johnson is Upgraded by Goldman to Neutral. Earlier the firm had a rating of Sell on the company shares. The Rating was issued on Mar 14, 2016.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.